Floatz logo

FLUOROURACILUM

Lymphoma, T-Cell, Peripheral

Fox Chase Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Lymphoma, T-Cell, Peripheral cohort.

Asset / SponsorPhaseRating
Romidepsin
University of Virginia
Phase 3BBB
Eloxatin
The Lymphoma Academic Research Organisation
Phase 2BB
Calcium folinate pentahydrate
Fox Chase Cancer Center
Phase 2BB
PEGFILGRASTIM
City of Hope Medical Center
Phase 2B
Tenalisib
Rhizen Pharmaceuticals SA
Phase 2B

View all 16 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →